The history of collaboration in acute promyelocytic leukemia (APL) research
Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel
What’s next for inotuzumab ozogamicin in ALL?
Why the rapid development of new drugs poses new challenges
The role of blinatumomab in ALL